The starting line
Top 30 institutional markets. No defensible read on where price, share or buyer demand was actually moving.
This MedTech leader sells into hospitals, IDNs and GPOs across more than thirty markets, mostly through distributors. Its commercial engine depends on knowing four things in every market: where ASPs are moving, who is holding share, which buyers are penetrating which categories, and what is driving local demand. None of that was visible through a single, trusted lens.
Distributor reports gave one read. External syndicated data gave another. Internal estimates filled the gaps. The numbers rarely agreed. Procedure-volume data refreshed on lags that made forecasting an act of faith. Tender opportunities were navigated manually, which is to say slowly and inconsistently. Product introduction calls, differentiation strategy and sales-force coverage were being made on a stack of patchwork inputs nobody could fully defend.
The leadership team did not need more data. They needed one defensible read across all of it.
30
Top institutional markets in scope
3+
External data sources patched together per market
Mths
Lag on procedure-volume data
Manual
Tender navigation and competitive analysis
In practice the cost was strategic, not operational. Forecasts missed. Sales force was pointed at markets where the share opportunity was not actually growing. New-product launches were timed against ASP movements that were already months stale. Differentiation calls were made on gut feel because the data underneath them could not survive a hard question from the board.
We were making product, pricing and sales-force calls on a market view we could not defend in a board meeting.
— Head of Strategy and Commercial Excellence (role anonymised)